{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:04:33Z","timestamp":1768568673556,"version":"3.49.0"},"posted":{"date-parts":[[2025,2,25]]},"group-title":"Psychiatry and Clinical Psychology","reference-count":107,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,2,25]]},"abstract":"<jats:title>Summary<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Schizophrenia and related disorders (SRD) are characterized by positive and negative symptoms, such as anhedonia and avolition. There are no current FDA approved treatments for negative symptoms, which is a critical gap in our treatment of people with SRDs, since they are a major determinant of functional impairment. An emerging literature suggests that SRDs have a relationship with immune function and inflammation. Recently an SRD subgroup with high inflammation and elevated levels of anti-gliadin antibodies (AGA) of immunoglobulin G type (IgG) ha\n                    <jats:bold>s<\/jats:bold>\n                    been characterized. Negative symptom improvement has been previously observed with gluten removal in this subgroup in two small clinical trials.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We conducted a 5-week confirmatory double-blind placebo-controlled trial of a gluten free diet (GFD) versus gluten-containing diet (GCD) for negative symptoms in people with SRD who have elevated AGA IgG (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03183609\">NCT03183609<\/jats:ext-link>\n                    ). Participants were between the ages of 18-64 years, had baseline negative symptoms and a diagnosis of schizophrenia or schizoaffective disorder. Those included were screened for an AGA IgG &gt;20 U, no serologic evidence of celiac disease, and stable antipsychotic treatment and dose. All participants were inpatients, received a GFD and were randomized to 30 grams of gluten or rice flour daily delivered in protein shakes. The Clinical Assessment Interview for Negative Symptoms (CAINS) Motivation and Pleasure (MAP) scale was the primary outcome measure. We also examined the CAINS Expressivity (EXP) scale, the Scale for the Assessment of Negative Symptoms (SANS), the Brief Psychiatric Rating Scale (BPRS), the MATRICS Consensus Cognitive Battery (MCCB) and conducted regular side effect screening and laboratory measures for safety.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>\n                    Between 2018 and 2024, we included 39 participants (N=21 GFD and N=18 GCD). There was a significant improvement over time in the CAINS MAP (treatment X time\n                    <jats:italic>df<\/jats:italic>\n                    =30.1,\n                    <jats:italic>F<\/jats:italic>\n                    =2.78,\n                    <jats:italic>p<\/jats:italic>\n                    =0.045) in the GFD compared to GCD, but no significant change in the CAINS EXP, the SANS, BPRS or MCCB. The diet was well tolerated; the most frequently occurring side effects were constipation (38.1% GFD, 33.3% GCD), sedation (33.3% GFD, 50% GCD), dry mouth (33.3% GFD, 33.3% GCD), headache (33.3% GFD, 27.8% GCD), and insomnia (33.3% GFD, 27.8% GCD).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>This is the first large scale double-blind randomized clinical trial in SRD with AGA IgG+. This replication of smaller studies suggests that negative symptoms, particularly anhedonia and avolition may be improved. However, we did not replicate our previous finding of cognitive improvement and COVID-19 likely impacted the extent of improvement in negative symptoms due to quarantines and lockdowns. More work is needed to determine the mechanism of action of gluten removal in this subgroup with hopes of developing new treatment targets for motivational deficits of this illness.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.02.24.25322813","type":"posted-content","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:15:15Z","timestamp":1740528915000},"source":"Crossref","is-referenced-by-count":0,"title":["Randomized Double Blind Inpatient Study of a Gluten-Free Diet in Persons with Schizophrenia"],"prefix":"10.64898","author":[{"given":"Deanna L.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.O.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica V.","family":"Talor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025022721250655000_2025.02.24.25322813v1.1","doi-asserted-by":"publisher","DOI":"10.1080\/13803390500360539"},{"key":"2025022721250655000_2025.02.24.25322813v1.2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010042"},{"key":"2025022721250655000_2025.02.24.25322813v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.73"},{"key":"2025022721250655000_2025.02.24.25322813v1.4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101358"},{"key":"2025022721250655000_2025.02.24.25322813v1.5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.08010031"},{"key":"2025022721250655000_2025.02.24.25322813v1.6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbi.2019.06.031","article-title":"Childhood infections and schizophrenia: The impact of parental SES and mental illness, and childhood adversities","volume":"81","year":"2019","journal-title":"Brain Behav Immun"},{"key":"2025022721250655000_2025.02.24.25322813v1.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066647"},{"key":"2025022721250655000_2025.02.24.25322813v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.01.001"},{"issue":"5","key":"2025022721250655000_2025.02.24.25322813v1.9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000448054","article-title":"Prenatal Inflammation, Infections and Mental Disorders","volume":"49","year":"2016","journal-title":"Psychopathology"},{"key":"2025022721250655000_2025.02.24.25322813v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.01.030"},{"key":"2025022721250655000_2025.02.24.25322813v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.06.003"},{"key":"2025022721250655000_2025.02.24.25322813v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.04.013"},{"key":"2025022721250655000_2025.02.24.25322813v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nature16549"},{"key":"2025022721250655000_2025.02.24.25322813v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0574-0"},{"key":"2025022721250655000_2025.02.24.25322813v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature08186"},{"key":"2025022721250655000_2025.02.24.25322813v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.04.025"},{"key":"2025022721250655000_2025.02.24.25322813v1.17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-126"},{"issue":"12","key":"2025022721250655000_2025.02.24.25322813v1.18","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1038\/tp.2016.238","article-title":"Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation","volume":"6","year":"2016","journal-title":"Transl Psychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.521"},{"key":"2025022721250655000_2025.02.24.25322813v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(96)00099-0"},{"issue":"9442","key":"2025022721250655000_2025.02.24.25322813v1.21","first-page":"1312","volume-title":"Lancet","volume":"364","year":"2004"},{"key":"2025022721250655000_2025.02.24.25322813v1.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1966.tb01920.x"},{"key":"2025022721250655000_2025.02.24.25322813v1.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1966.tb01912.x"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.24","first-page":"010410","article-title":"Prevalence of schizophrenia in China between 1990 and 2010","volume":"5","year":"2015","journal-title":"J Glob Health"},{"issue":"3","key":"2025022721250655000_2025.02.24.25322813v1.25","first-page":"385","article-title":"Is schizophrenia rare if grain is rare?","volume":"19","year":"1984","journal-title":"Biol Psychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i375"},{"key":"2025022721250655000_2025.02.24.25322813v1.27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.115.522.595"},{"issue":"5","key":"2025022721250655000_2025.02.24.25322813v1.28","first-page":"627","article-title":"Lack of effect of a gluten-free diet on neuroleptic blood levels in schizophrenic patients","volume":"17","year":"1982","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2025022721250655000_2025.02.24.25322813v1.29","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1176\/ajp.138.9.1208","article-title":"Wheat gluten challenge in schizophrenic patients","volume":"138","year":"1981","journal-title":"Am J Psychiatry"},{"issue":"11","key":"2025022721250655000_2025.02.24.25322813v1.30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1176\/ajp.135.11.1417","article-title":"Another look at gluten in schizophrenia","volume":"135","year":"1978","journal-title":"Am J Psychiatry"},{"issue":"1 Pt 1","key":"2025022721250655000_2025.02.24.25322813v1.31","first-page":"132","article-title":"Celiac disease","volume":"23","year":"1959","journal-title":"Pediatrics"},{"key":"2025022721250655000_2025.02.24.25322813v1.32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246624"},{"key":"2025022721250655000_2025.02.24.25322813v1.33","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290030055010"},{"key":"2025022721250655000_2025.02.24.25322813v1.34","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.148.4.447"},{"key":"2025022721250655000_2025.02.24.25322813v1.35","doi-asserted-by":"crossref","unstructured":"Delgadillo J , Lutz W. A Development Pathway Towards Precision Mental Health Care. JAMA Psychiatry. 2020.","DOI":"10.1001\/jamapsychiatry.2020.1048"},{"key":"2025022721250655000_2025.02.24.25322813v1.36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14081018"},{"key":"2025022721250655000_2025.02.24.25322813v1.37","doi-asserted-by":"crossref","unstructured":"Phillips ML , Kendler KS . Three Important Considerations for Studies Examining Pathophysiological Pathways in Psychiatric Illness: In-depth Phenotyping, Biological Assessment, and Causal Inferences. JAMA Psychiatry. 2021.","DOI":"10.1001\/jamapsychiatry.2021.0022"},{"key":"2025022721250655000_2025.02.24.25322813v1.38","doi-asserted-by":"crossref","unstructured":"Kendler KS . From Many to One to Many-the Search for Causes of Psychiatric Illness. JAMA Psychiatry. 2019.","DOI":"10.1001\/jamapsychiatry.2019.1200"},{"key":"2025022721250655000_2025.02.24.25322813v1.39","doi-asserted-by":"crossref","unstructured":"Strauss JS , Carpenter WT, Jr ., Bartko JJ . The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974(11):61\u20139.","DOI":"10.1093\/schbul\/1.11.61"},{"key":"2025022721250655000_2025.02.24.25322813v1.40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.schres.2017.08.051","article-title":"Gliadin-related antibodies in schizophrenia","volume":"195","year":"2018","journal-title":"Schizophr Res"},{"key":"2025022721250655000_2025.02.24.25322813v1.41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2023.02.027","article-title":"The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia","volume":"256","year":"2023","journal-title":"Schizophr Res"},{"key":"2025022721250655000_2025.02.24.25322813v1.42","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv108"},{"issue":"2-3","key":"2025022721250655000_2025.02.24.25322813v1.43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.schres.2014.09.023","article-title":"Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia","volume":"159","year":"2014","journal-title":"Schizophr Res"},{"issue":"2-3","key":"2025022721250655000_2025.02.24.25322813v1.44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.schres.2013.12.001","article-title":"Biomarkers of gluten sensitivity in patients with non-affective psychosis: a meta-analysis","volume":"152","year":"2014","journal-title":"Schizophr Res"},{"issue":"7","key":"2025022721250655000_2025.02.24.25322813v1.45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/15622975.2012.747699","article-title":"Elevated gliadin antibody levels in individuals with schizophrenia","volume":"14","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.46","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2012.685537"},{"key":"2025022721250655000_2025.02.24.25322813v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.06.011"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1503\/jpn.180174","article-title":"Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study","volume":"44","year":"2019","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"2025022721250655000_2025.02.24.25322813v1.49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0000000000001197","article-title":"The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G","volume":"40","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"2025022721250655000_2025.02.24.25322813v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3257"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.51","first-page":"66","article-title":"Assessment of capacity to give consent to research participation: state-of-the-art and beyond","volume":"1","year":"1998","journal-title":"J Health Care Law Policy"},{"key":"2025022721250655000_2025.02.24.25322813v1.52","unstructured":"First MB , Gibbon M , Spitzer RL , Williams JBW , Benjamin LS . Structured clinical interview for DSM-IV axis II personality disorders, (SCID-II). Washington, DC: American Psychiatric Press; 1997."},{"key":"2025022721250655000_2025.02.24.25322813v1.53","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080032005"},{"key":"2025022721250655000_2025.02.24.25322813v1.54","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080038006"},{"issue":"14","key":"2025022721250655000_2025.02.24.25322813v1.55","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3748\/wjg.v24.i14.1521","article-title":"Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm","volume":"24","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025022721250655000_2025.02.24.25322813v1.56","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290070020005"},{"key":"2025022721250655000_2025.02.24.25322813v1.57","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22681"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.58","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease","volume":"85","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"2025022721250655000_2025.02.24.25322813v1.59","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290070025006"},{"key":"2025022721250655000_2025.02.24.25322813v1.60","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06081358"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000720","article-title":"A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia","volume":"37","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2025022721250655000_2025.02.24.25322813v1.62","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.63","first-page":"122","article-title":"Discussion: recent developments in ascertainment and scaling of the BPRS","volume":"24","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"2025022721250655000_2025.02.24.25322813v1.64","doi-asserted-by":"crossref","unstructured":"Addington D , Addington J , Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993(22):39\u201344.","DOI":"10.1192\/S0007125000292581"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.65","first-page":"247","article-title":"A depression rating scale for schizophrenics","volume":"3","year":"1990","journal-title":"SchizophrRes"},{"key":"2025022721250655000_2025.02.24.25322813v1.66","first-page":"s7","article-title":"Symptom rating scales and outcome in schizophrenia","volume":"50","year":"2007","journal-title":"Br J Psychiatry Suppl"},{"key":"2025022721250655000_2025.02.24.25322813v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.04.005"},{"issue":"6","key":"2025022721250655000_2025.02.24.25322813v1.68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/070674370605100609","article-title":"Detection of depression in acute schizophrenia: sensitivity and specificity of 2 standard observer rating scales","volume":"51","year":"2006","journal-title":"CanJ Psychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.69","unstructured":"Guy W , National Institute of Mental Health. Psychopharmacology Research B, Early Clinical Drug Evaluation P. ECDEU assessment manual for psychopharmacology, revised. Rev. ed. Rockville, Md: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"2025022721250655000_2025.02.24.25322813v1.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.09.011"},{"key":"2025022721250655000_2025.02.24.25322813v1.71","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010043"},{"key":"2025022721250655000_2025.02.24.25322813v1.72","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"2025022721250655000_2025.02.24.25322813v1.73","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90148-0"},{"issue":"2","key":"2025022721250655000_2025.02.24.25322813v1.74","first-page":"129","volume-title":"Annals of the Academy of Medicine","volume":"23","year":"1994"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.75","first-page":"75","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease","volume":"7","year":"1998","journal-title":"QualLife Res"},{"key":"2025022721250655000_2025.02.24.25322813v1.76","first-page":"11","article-title":"A rating scale for extrapyramidal side effects","volume":"212","year":"1970","journal-title":"Acta PsychiatrScandSuppl"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale--revisited","volume":"17","year":"2003","journal-title":"JPsychopharmacol"},{"key":"2025022721250655000_2025.02.24.25322813v1.78","first-page":"672","article-title":"A rating scale for drug-induced akathisia","volume":"154","year":"1989","journal-title":"BrJPsychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuroimage.2015.10.050","article-title":"The common genetic influence over processing speed and white matter microstructure: Evidence from the Old Order Amish and Human Connectome Projects","volume":"125","year":"2016","journal-title":"Neuroimage"},{"key":"2025022721250655000_2025.02.24.25322813v1.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2013.05.041"},{"key":"2025022721250655000_2025.02.24.25322813v1.81","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.10211"},{"key":"2025022721250655000_2025.02.24.25322813v1.82","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1572"},{"key":"2025022721250655000_2025.02.24.25322813v1.83","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.154"},{"key":"2025022721250655000_2025.02.24.25322813v1.84","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00297-2"},{"issue":"7","key":"2025022721250655000_2025.02.24.25322813v1.85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/14737175.2022.2092402","article-title":"Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia","volume":"22","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"2025022721250655000_2025.02.24.25322813v1.86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2016.07.013","article-title":"Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment","volume":"186","year":"2017","journal-title":"Schizophr Res"},{"issue":"2","key":"2025022721250655000_2025.02.24.25322813v1.87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/wps.20879","article-title":"Clinical relevance of general and specific dimensions in bifactor models of psychotic disorders","volume":"20","year":"2021","journal-title":"World Psychiatry"},{"key":"2025022721250655000_2025.02.24.25322813v1.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.01.015"},{"key":"2025022721250655000_2025.02.24.25322813v1.89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.psychres.2016.01.001","article-title":"An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia","volume":"236","year":"2016","journal-title":"Psychiatry Res"},{"issue":"16","key":"2025022721250655000_2025.02.24.25322813v1.90","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1017\/S0033291718000442","article-title":"What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors","volume":"48","year":"2018","journal-title":"Psychol Med"},{"key":"2025022721250655000_2025.02.24.25322813v1.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.01.004"},{"key":"2025022721250655000_2025.02.24.25322813v1.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.10.017"},{"key":"2025022721250655000_2025.02.24.25322813v1.93","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn094"},{"key":"2025022721250655000_2025.02.24.25322813v1.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.04.019"},{"key":"2025022721250655000_2025.02.24.25322813v1.95","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20167"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.96","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamapsychiatry.2017.4607","article-title":"Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis","volume":"75","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.97","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/wps.20700","article-title":"The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients","volume":"19","year":"2020","journal-title":"World Psychiatry"},{"issue":"5","key":"2025022721250655000_2025.02.24.25322813v1.98","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamapsychiatry.2020.4614","article-title":"Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses","volume":"78","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"2025022721250655000_2025.02.24.25322813v1.99","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/PSY.0000000000000352","article-title":"Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies","volume":"78","year":"2016","journal-title":"Psychosom Med"},{"issue":"6","key":"2025022721250655000_2025.02.24.25322813v1.100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/1871527317666180702160921","article-title":"The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling","volume":"17","year":"2018","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"2025022721250655000_2025.02.24.25322813v1.101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/j.2051-5545.2008.tb00181.x","article-title":"Deficit schizophrenia: an update","volume":"7","year":"2008","journal-title":"World Psychiatry"},{"issue":"10","key":"2025022721250655000_2025.02.24.25322813v1.102","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1038\/s41380-023-02221-w","article-title":"Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses","volume":"28","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2025022721250655000_2025.02.24.25322813v1.103","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/schbul\/sbae054","article-title":"Topological Perturbations in the Functional Connectome Support the Deficit\/Non-deficit Distinction in Antipsychotic Medication-Naive First Episode Psychosis Patients","volume":"50","year":"2024","journal-title":"Schizophr Bull"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-021-01260-0","article-title":"The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia","volume":"272","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"2025022721250655000_2025.02.24.25322813v1.105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41398-021-01196-y","article-title":"The prevalence of depressive and anxiety symptoms and their associations with quality of life among clinically stable older patients with psychiatric disorders during the COVID-19 pandemic","volume":"11","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"2","key":"2025022721250655000_2025.02.24.25322813v1.106","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.pra.0000369971.64908.dc","article-title":"How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone","volume":"16","year":"2010","journal-title":"J Psychiatr Pract"},{"key":"2025022721250655000_2025.02.24.25322813v1.107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2021.12.028","article-title":"Can the current schizophrenia construct endure?","volume":"242","year":"2022","journal-title":"Schizophr Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.02.24.25322813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:29:05Z","timestamp":1768508945000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.02.24.25322813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":107,"URL":"https:\/\/doi.org\/10.1101\/2025.02.24.25322813","relation":{},"subject":[],"published":{"date-parts":[[2025,2,25]]},"subtype":"preprint"}}